Sol-Gel Technologies Ltd. (SLGL)

Market Cap	235.63M +1,066.5%
Revenue (ttm)	18.47M +52.6%
Net Income	-1.05M
EPS	-0.37
Shares Out	3.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,421
Open	76.88
Previous Close	75.30
Day's Range	72.00 - 76.88
52-Week Range	6.85 - 97.97
Beta	1.13
Analysts	Strong Buy
Price Target	147.00 (+103.94%)
Earnings Date	May 28, 2026

About SLGL

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 23, 2018
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: SLGL
• Website: https://www.sol-gel.com

Financial Performance

In 2025, Sol-Gel Technologies's revenue was $19.39 million, an increase of 68.04% compared to the previous year's $11.54 million. Losses were -$6.13 million, -42.09% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for SLGL stock is "Strong Buy." The 12-month stock price target is $147.0, which is an increase of 103.94% from the latest price.

Price Target

$147.0

(103.94% upside)

Analyst Consensus: Strong Buy